U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07331818) titled 'Luspatercept in Patients Affected With Rare Inherited Anemias' on Dec. 05, 2025.
Brief Summary: This is a prospective multicenter phase II basket trial evaluating Luspatercept in patients affected with rare inherited anemias
Study Start Date: Jan. 15
Study Type: INTERVENTIONAL
Condition:
Hereditary Red Blood Cell Disorder (Disorder)
Intervention:
DRUG: Reblozyl
Reblozyl 25 mg powder for solution for injection / Reblozyl 75 mg powder for solution for injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: EuroBloodNet Association
Disclaimer: Curated by HT Syndication....